Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
  • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
  • A61K31/728—Hyaluronic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/10—Drugs for disorders of the urinary system of the bladder
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/16—Emollients or protectives, e.g. against radiation
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present invention relates to a method for preventing, reducing and treating radiation cystitis caused by external beam radiation therapy, which impinges on the urinary bladder and associated structures, comprising administering into the urinary bladder and associated structures a composition comprising hyaluronic acid (HA) having an average molecular weight of not less than 2 X 10 5 Daltons and a pharmaceutically acceptable carrier.
• HA hyaluronic acid
• Acute effects of radiotherapy on normal tissue are observed during and immediately following a course of radiotherapy.
• the major complication of radiotherapy, which impinges on the bladder area, is its effect on urinary bladder function resulting in radiation cystitis.
• Radiation cystitis is defined in terms of bladder pain, increased urinary urgency, increased voiding frequency and increased nocturia. Its duration is usually 3 to 6 months, but can be 24 months or longer.
• serious delayed urinary complications involving lifestyle altering symptoms or requiring hospitalization are observed in 2-7% of patients undergoing radiotherapy for prostate cancer. It is hypothesized that radiation of the bladder area induces disruption of the glycosaminoglycan (GAG) layer, which lines the inner surface of the urinary bladder.
• GAG glycosaminoglycan
• This GAG layer consists of mucopolysaccharides attached to a core protein that, in turn, is bound to a central hyaluronic acid string.
• This highly viscous, highly hydrophilic GAG layer protects the bladder epithelium against irritants in the urine including, but not limited to, microorganisms, pathogens, microcrystals, proteins, calcium, urea and carcinogens (Nickel et al. 1993. Journal of Urology, 149:716). When this protective barrier is damaged, the bladder epithelium becomes permeable to urinary irritants, resulting in symptoms of bladder pain, increased urinary urgency, increased voiding frequency and increased nocturia.
• Other symptoms can include, but are not limited to, dysuria, heamaturia, arthritis, spastic colon, low grade fever and irritability.
• Methods for treating existing interstitial cystitis include, but are not limited to, hydraulic distention of the urinary bladder, oral amitriptyline or sodium pentosanpolysulfate, intravesical instillation of dimethyl-sulfoxide, oxychlorosene sodium, silver nitrate, heparin, angiostatic steroids, pentosanpolysulfate and hyaluronic acid.
• a method for protecting the urinary bladder from the effects of the radiotherapy so as to prevent, reduce and treat the radiation cystitis caused by radiotherapy that impinges on the bladder area comprising administering into the bladder of the animal a composition comprising HA, having an average molecular weight of not less than 2 X 10 5 Daltons, and a pharmaceutically acceptable carrier, wherein the HA is administered in an amount effective to prevent, reduce and treat the radiation cystitis. It is an object of the present invention to provide a method for preventing radiation cystitis.
• bladedder refers to the internal surface of the urinary bladder and its associated structures in an animal, including a human.
• associated structures refers to the renal pelvis, ureters and urethra in an animal, including a human.
• the phrase "internal surface of the urinary bladder” refers to the transitional epithelium, which lines the urinary bladder and associated structures in an animal, including a human.
• radiation cystitis refers to symptoms selected from the group consisting of bladder pain, increased urinary urgency, increased voiding frequency and increased nocturia that are associated with radiotherapy that impinges on the bladder.
• HA is highly viscous, highly electronegative and highly hydrophilic. It has been found that contacting the bladder with a solution containing an effective concentration of HA and salts thereof, having an average molecular weight of not less than 2 X 10 5 Daltons, prior to radiotherapy, during a course of radiotherapy treatments, unexpectedly prevents or reduces the symptoms of radiation cystitis usually caused by radiotherapy for diseases such as, but not limited to, prostate cancer, bladder cancer, rectal cancer, uterine cancer and cervical cancer.
• the HN has a molecular weight range of about 2 X 10 5 to about 3.1 X 10 6 Daltons, more preferably of about 2 X 10 5 to about 1.9 X 10 6 Daltons and most preferably of about 2.5 X 10 5 to about 1.2 X 10 6 Daltons.
• hyaluronic acid Various methods for the isolation, purification and fractionation of hyaluronic acid are available. These include fractionation of HA derived from cartilage, fractionation of hyaluronic acid derived from bacteria including, but not limited to, streptococcal species, and the purchase of molecular weight fractions of hyaluronic acid from commercial sources including, but not limited to, Fluka Chemical Corporation, Ronkonkoma, ⁇ Y, Genzyme Corporation, Cambridge, MA and Lifecore Biomedical, Inc., Chaska, M ⁇ .
• the HA is solubilized in a pharmaceutically acceptable carrier including, but not limited to, physiological saline and phosphate buffered saline.
• a pharmaceutically acceptable carrier including, but not limited to, physiological saline and phosphate buffered saline.
• any of the pharmaceutical carriers known to those skilled in the art to be acceptable for administration into the bladder of an animal can be used in the present invention.
• HA is administered into the bladder in an amount between about 5 mg and about 1000 mg, more preferably between about 10 mg and about 500 mg and most preferably between about 25 mg and about 100 mg.
• concentration of HA administered into the bladder is preferably from about 0.01 mg/ml to about 100 mg/ml, more preferably from about 0.1 mg/ml to about 50 mg/ml and most preferably from about 0.4 mg/ml to about 25 mg/ml.
• the volume of HA solution administered into the bladder is between about 1 ml and about 500 ml, more preferably between about 10 ml and about 250 ml and most preferably between about 20 ml and about 100 ml.
• HA solution can be administered into the bladder prior to a radiotherapy treatment and /or subsequent to a radiotherapy treatment. It can be used in conjunction with each radiotherapy treatment or in conjunction with any multiple of radiotherapy treatments. To treat radiation cystitis, HA solution can be administered into the bladder one or more times after completion of a course of radiotherapy treatments.
• HA solution Prior to installation of HN solution, residual urine is removed from the bladder using a sterile urethral catheter. The HA solution is then administered into the bladder using, but not limited to, a sterile urethral catheter.
• HA solution is administered into the bladder from about 1 minute to about 4 hours prior to a radiotherapy treatment or subsequent to a radiotherapy treatment, more preferably from about 2 minutes to about 2 hours and most preferably from about 5 minutes to about 1 hour.
• HA solution also is administered into the bladder after completion of a course of radiotherapy treatments.
• the HA solution remains in contact with the bladder for a total time of about 1 minute to about 4 hours, more preferably from about 2 minutes to about 2 hours and most preferably from about 5 minutes to about 1 hour.
• the HA solution may further include agents such as, but not limited to, antiseptic, antibacterial, antifungal, immunotherapeutic, immunosuppressive, chemotherapeutic, pH modifying, and glycosaminoglycan (in addition to HA) agents.
• agents such as, but not limited to, antiseptic, antibacterial, antifungal, immunotherapeutic, immunosuppressive, chemotherapeutic, pH modifying, and glycosaminoglycan (in addition to HA) agents.
• agents such as, but not limited to, antiseptic, antibacterial, antifungal, immunotherapeutic, immunosuppressive, chemotherapeutic, pH modifying, and glycosaminoglycan (in addition to HA) agents.
• the agent and the amount of the agent to be included in the HA solution are well within the determination of those skilled in the art.
• Antibacterial agents include, but are not limited to, aminoglycoside, cephalosporin, gentamycin, macrolide, nitrofurantoin, penicillin, quinolone, sulphonamide, tetracycline, trimethoprim, bacitracin, neomycin, chlorhexidine and mandelamine.
• Antifungal (antiyeast) agents include, but are not limited to, amphotericin B and fluconazole.
• Immunotherapeutic agents include, but are not limited to, bacterial cell extracts, mycobacterial cell wall extracts, live and inactivated bacillus Calmette-Guerin (BCG), BCG extracts, cytokines, interferons, interleukins, prostaglandins, and immune stimulants of viral, chemical and molecular biological origin effective for treating disorders of the bladder and the associated cystitis.
• Immunosuppressive agents include, but not limited to, prostaglandins (PGE 2 ) and corticosteroids.
• Chemotherapeutic agents include, but are not limited to, cisplatin, cyclophosphamide, doxorubicin (adriamycin), vincristine, mitomicin-C and thiotepa.
• pH modifying agents include, but are not limited to, sodium acid phosphate and sodium bicarbonate.
• Glycosaminoglycans (in addition to HA) include, but are not limited to, heparin, heparan sulfates, pentosanpolysulfate, dermatan sulfates, chondroitin sulfates and keratanosulfates.
• Inclusion criteria include patients >18 years of age with histologically documented stage T2 or T3 (T3a or T3b) prostate carcinoma and PSA within normal range following anti-androgen therapy ( ⁇ 60 years, upper limit of 4.0 ng/ml; 60-69 years, upper limit 4.5 ng/ml; >70 years, upper limit of 6.5 ng/ml). These patients have an ECOG performance status for cancer clinical trials of 0, 1 or 2 (Oken et al. American Journal of Clinical Oncology (CCT), 5_:649, 1982), a five- year life expectancy and are available for at least one year. They have normal white blood cell count, platelets, international normalized ratio of prothrombin time and partial thromboplastin time.
• Exclusion criteria include patients being treated with investigational drugs, anticholinergics, urinary antiseptics, antihistamines, potent analgesics, corticosteroids, anti-inflammatory agents or any medication or active treatment for interstitial cystitis within 14 days of radiotherapy, patients with clinical evidence of metastatic disease, multiple transurethral resections of bladder tumors or recurring bladder infections or stones, collagen, vascular, or autoimmune disease, ulcerative colitis or regional enteritis, multiple prior abdominal surgical procedures, renal insufficiency (Blood Urea Nitrogen >15 mmol/L, serum creatinine >250 ⁇ mmol/L), hepatic insufficiency (Alanine Aminotransferase and Aspartate Aminotransferase >50% above upper limit of normal), uncontrolled congestive heart failure or uncontrolled ischemic . heart disease and previous chemotherapy and /or radiation therapy.
• Pre-therapy pain scale, urinary urgency (urgency) scale, voiding frequency and nocturia are obtained 3 times during week 0 (pre- therapy) using patient recorded (diary) assessments.
• Pre-therapy symptom index and problem index is assessed 1 time during week 0 using patient administered questionnaires.
• the scales and indices used are known to those skilled in the art.
• Pain scales include the Visual Analog Scale (VAS 0-lOcm), the 6 Point Behavioral Rating Scale (BRS-6) and 5 Point Verbal Rating Scale (VRS-5).
• Urgency is defined as a strong need to urinate with little or no warning.
• Urgency scales include the Visual Analog Scale (VAS 0- 10cm) and the Point Verbal Rating Scale (VRS-5).
• Voiding frequency measures the frequency of urination during a 24 hour time period and nocturia measures the frequency of waking up to urinate during sleep.
• the symptom index measures radiation cystitis symptoms, which occur during a specified time period (O'Leary et al, Journal of Urology 155(515):439A, 1996).
• the problem index measures lifestyle problems related to radiation cystitis.
• a radiotherapy dose of 18-220 cGY per day is given 5 days per week for 6 weeks and 3 times per week for 1 additional week (33 treatments) resulting in a total dose of 6600 cGY.
• HA solution is administered into the bladder about 30 minutes prior to radiotherapy 3 times per week (alternate days) for 6 weeks and 2 times per week for 1 additional week (20 treatments).
• a urethral catheter is introduced into the bladder under aseptic conditions, residual urine is removed and the volume recorded.
• the HN solution is maintained in the bladder for about 30 minutes, the HN solution is voided and the radiotherapy is begun.
• Example 5 During therapy assessment During the 7 weeks of radiotherapy, pain scale, urgency scale, voiding frequency and nocturia are obtained 3 times per week using patient recorded (diary) assessments as in Example 2. Symptom index and problem index is assessed at weeks 4 and 8 using patient administered questionnaires as in Example 2.
• Patients selected as in Example 1, receive radiotherapy as in Example 3. These patients have increases in average pain scale >1.0, average urgency scale of >1.0, average voiding frequency of >5 and average nocturia of >3 during weeks 6 and 7 of radiotherapy compared to week 0 and increases in symptom index of >3 and in problem index of >3 at week 8 compared to week 0.
• Example 1 Five patients, selected as in Example 1, elected to receive HA as in Example 4 prior to radiotherapy treatments during the course of their radiotherapy for prostate cancer as in Example 3.
• Table 1 shows results obtained for Patient A during weeks 1-7 of radiotherapy and at the completion of radiotherapy (week 8). Table 1
• week 1 As pre-therapy (week 0) data for pain scale, urgency scale, voiding frequency and nocturia were not available for this patient, week 1 averages were used as baseline.
• pain scale was 0.0 and increased to 0.2 during weeks 6 and 7 of radiotherapy.
• urgency scale was 0.0 and increased to 0.17 during weeks 6 and 7 of radiotherapy.
• voiding frequency was 8.0 and decreased to 7.3 during weeks 6 and 7 of radiotherapy.
• nocturia was 0.0 and increased to 1.7 during weeks 6 and 7 of radiotherapy.
• the symptom index decreased from 3 to 2 and the problem index increased from 0 to 1 between weeks 0 and 8.
• Table 2 shows results obtained for Patient B prior to radiotherapy (week 0), during radiotherapy (weeks 1-7) and at the completion of radiotherapy (week 8).
• Table 4 shows results obtained for Patient D prior to radiotherapy (week 0), during radiotherapy (weeks 1-7) and at the completion of radiotherapy (week 8).
• Patient D prior to radiotherapy during a course of radiotherapy treatments either prevented or reduced the pain, increased urgency, increased voiding frequency and increased nocturia usually associated with radiotherapy for the treatment of prostate cancer.
• Patient D showed no increase in average pain scale, a decrease in average urgency scale, minimal increases in average voiding frequency, average nocturia and problem index and a significant increase in symptom index. Therefore, patients administered HA into the bladder prior to radiotherapy treatments, during a course of radiotherapy that impinges on the bladder, did not develop the bladder pain, increased urinary urgency, increased voiding frequency and increased nocturia symptomatic of radiation cystitis.
• Example 1 Patients, selected as in Example 1, receive radiotherapy for 7 weeks as in Example 3. At week 8, each of these patients shows significant symptoms of radiation cystitis. At this time, each patient is treated with HA as in Example 4 except that the HA is administered 3 times per week (alternate days) for 6 weeks (weeks 8-13) for a total of 18 treatments or until the radiation cystitis symptoms resolve.
• Pre- therapy assessments, as in Example 2 are done during weeks 6 and 7 of radiotherapy.
• Therapy assessments, as in Example 5 are done during weeks 8-13 or until symptoms resolve.
• Final symptom index and problem index are done at week 14 or when radiation cystitis symptoms resolve.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Dermatology (AREA)
• Toxicology (AREA)
• Molecular Biology (AREA)
• Epidemiology (AREA)
• Gastroenterology & Hepatology (AREA)
• Urology & Nephrology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Polysaccharides And Polysaccharide Derivatives (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (2)

Family

ID=22304511

Family Applications (1)

Country Status (12)

Cited By (4)

Families Citing this family (7)

Family Cites Families (4)

• 1999
  • 1999-10-22 JP JP2000577997A patent/JP4685242B2/ja not_active Expired - Lifetime
  • 1999-10-22 AT AT99952186T patent/ATE264674T1/de active
  • 1999-10-22 DK DK99952186T patent/DK1124546T3/da active
  • 1999-10-22 AU AU64558/99A patent/AU761158B2/en not_active Ceased
  • 1999-10-22 US US09/830,063 patent/US6667296B1/en not_active Expired - Lifetime
  • 1999-10-22 EP EP99952186A patent/EP1124546B1/en not_active Expired - Lifetime
  • 1999-10-22 DE DE69916643T patent/DE69916643T2/de not_active Expired - Lifetime
  • 1999-10-22 ES ES99952186T patent/ES2219070T3/es not_active Expired - Lifetime
  • 1999-10-22 WO PCT/CA1999/000994 patent/WO2000024387A2/en not_active Ceased
  • 1999-10-22 NZ NZ511068A patent/NZ511068A/en not_active IP Right Cessation
  • 1999-10-22 PT PT99952186T patent/PT1124546E/pt unknown
  • 1999-10-22 CA CA002347110A patent/CA2347110C/en not_active Expired - Lifetime
• 2003
  • 2003-11-10 US US10/705,255 patent/US20040152662A1/en not_active Abandoned

Also Published As

Similar Documents

Legal Events